Genitourinary Cancer News

CHICAGO — The addition of atezolizumab to cabozantinib failed to improve clinical outcomes for patients with metastatic renal cell carcinoma who experienced progression on or after immune checkpoint inhibitor therapy, study results showed.

CHICAGO — Erdafitinib improved OS, PFS and objective response rate compared with chemotherapy among patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations.

CHICAGO — Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy.

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.

CHICAGO — First-line enfortumab vedotin-ejfv plus pembrolizumab conferred promising long-term outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, study results presented at ASCO Annual Meeting showed.

CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.

Metabolically healthy and unhealthy obesity appeared associated with increased risk for various obesity-associated cancer types, according to study results presented at European Congress on Obesity.

In this video, Andrew Katims, MD, discussed data regarding detection of renal cell carcinoma presented at the American Urological Association Annual Meeting.

In this video, Andrew Katims, MD, discussed data regarding radiologic imaging for renal cell carcinoma presented at the American Urological Association Annual Meeting.

Staffing shortages at radiation oncology clinics are causing treatment delays and increased patient anxiety, according to results of a national survey from American Society for Radiation Oncology.